Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VOLTAIRE-X in chronic plaque psoriasis
2016-002254-20Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- May 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in psoriasis comparing Continuous US-licensed Humira with Switching between BI 695501 and US-licensed Humira (2 arms). Primary endpoint: AUCtau 30-32. Started May 2017; status: completed.
02
Drugs
adalimumabadalimumab-adbm
03
Conditions
psoriasis
Beyond the preview
Go deeper on 2016-002254-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-002254-20.